A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy (VX17-659-105)

Details

Therapeutic category
Restore CFTR Function
Trial status
Completed Participating Centres
Phase
Phase III

Full title

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Trial Reference Number
108792
Trial type
Medication
Intervention
CFTR Modulators
Recruitment target
460
Last edited date
11/07/2018
CF sponsor
Vertex Pharmaceuticals Incorporated
CF sponsor type
Commercial

Who can take part?

Age
12+
Top inclusion criteria
  • Completed study drug treatment or scheduled visits in a parent study
  • Age 12 Years and older
  • Homozygous or heterozygous for F508del
Top exclusion criteria
  • History of drug intolerance in a parent study
  • Current participation in an investigational drug trial (other than a parent study)

Your donation will make a difference:

Select amount